Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease

Table 4

Comparison of the mean change in eGFR from baseline to final visit (ΔeGFR).

Studies	ΔeGFR (mL/min/1.73 m^2) ± SD
	Paricalcitol group	Placebo group	𝑃 value
Agarwal et al. [6]	−2.5±0.54	−3.0±0.53	𝑃=0.51
Abboud et al. [8] (TIW)	−2.9±0.61	−1.3±0.60	𝑃=0.066
Abboud et al. [8] (QD)	−1.6±1.01	−2.0±0.88	𝑃=0.78
Coyne et al. [9]	−2.52±0.526	−1.57±0.494	𝑃=0.187